Azurity Pharmaceuticals Announces The FDA Approval Of XIFYRMTM (Meloxicam Injection) For The Management Of Moderate-To-Severe Pain In Adults

2025-06-10 10:01:32

(MENAFN- PR Newswire)

WOBURN, Mass., June 10, 2025 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection), an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.

XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. XIFYRM provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required.

"XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," said Ron Scarboro, CEO at Azurity Pharmaceuticals. "XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies."

XIFYRM will be available in the coming weeks. For full prescribing information, including boxed warning and safety profile, please visit

About Azurity Pharmaceuticals:
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and ten key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people. For more information, visit .

SOURCE Azurity Pharmaceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN10062025003732001241ID1109656417

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.